NanoMab Technology Ltd was founded in 2016 by Dr. Hong Hoi Ting and Mr. Henry Ho following a collaboration with Professor Yakun Wan, an expert in the development of camelid single domain antibodies.
The company established its main operating site in Shanghai, PRC where it continues to have its major scientific activities. In 2018, the company set up a collaboration with King’s College London and the following year began to work with the University Hospital in Aachen. In June 2019, NanoMab entered into a commercial agreement with LantheusMedical Imaging Inc.
In 2020, NanoMab set up an operation in the UK ahead of transferring its headquarters to London.
Platform built and EU clinical Phase 1&2
• EU Phase 1&2 Q4 2020
• FIH trial scheduled for Q4 2020
• Product development commenced (Q1 2020)
Company relocates operations to the UK
NM-01 human trials commenced (PRC)
•PD-L1 SPECT-CT 29 patients
•PD-L1 PET-CT 4 patients
NM-02 imaging human trials commenced
•FIH HER2 SPECT-CT 9 patients
Commercial agreement: Global agreement signed with Lantheus Medical Imaging Inc. for development of NM-01 for clinical research.
Patient testing: First in human (FIH) trial at a PRC 3A hospital, scientific publication in collaboration with
King’s College, London (Results published)
Animal in-vivo trials, production preparation/optimisation, product stability, patent application
Early testing: Team formation, early product samples and in vitro test
Drug target planning & design by HK & PRC scientists (Incubation)